mProX™ Human P2RY14 Stable Cell Line

Product Information

Target Protein

P2RY14

Target Family

P2Y Family

Target Protein Species

Human

Host Cell Type

Ba/F3; CHO-K1; HEK293

Target Classification

GPCR Cell Lines

Target Research Area

Cancer Research; CNS Research

Related Diseases

Arthrogryposis; Endometrial Mixed Adenocarcinoma

Gene ID

9934

UniProt ID

Q15391

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

UDP-glucose, a P2RY14 agonist, mediates the enzyme's action. P2RY14 and UDP-glucose can combine to prevent human U373 MG cells from accumulating cAMP in response to forskolin stimulation. P2RY14 is widely expressed in peripheral tissues and numerous brain areas in both humans and rats. Because anti-P2RY14 antibodies can be recovered from a subpopulation of hematopoietic cells, P2RY14 is enriched and controls the G0 cell cycle status in hematopoietic cells in the fetal bone marrow but not in fetal liver. Human immature monocyte-derived dendritic cells express P2RY14, and it has been suggested that this interaction with its agonist, uridine diphosphogulcose, increases intracellular calcium. P2RY14 is also strongly expressed in leukocytes and other immune/inflammatory cells, and it is increased in response to an immunologic insult, indicating that it is crucial for immunological or inflammatory responses. The customized P2RY14 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Michael

Very easy to use for drug screening and fast turnaround. Sep 28 2022

chat Verified Customer

chat Daniel

I have always got fast and friendly response. Jan 30 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 P2RY14 expression

Analysis of gene expression in PKI-587-sensitive and PKI-587-resistant sets of cell lines was done using RNA sequencing data. AKT, ERK1/2, S6K, and p38 phosphorylation in the entire cell lysate was examined using a Western blot.

Ref: Shah, Kinjal, Sausan A. Moharram, and Julhash U. Kazi. "Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression." Clinical epigenetics 10 (2018): 1-5.

Pubmed: 29951132

DOI: 10.1186/s13148-018-0516-x

Research Highlights

According to this study, acute leukemia cells that are resistant to PI3K/mTOR suppression show overexpression of the GPCR P2RY14, which is linked to the activation of ERK signaling and has a role in patient survival.
Shah, Kinjal, Sausan A. Moharram, and Julhash U. Kazi. "Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression." Clinical epigenetics 10 (2018): 1-5.
Pubmed: 29951132 DOI: 10.1186/s13148-018-0516-x

P2RY14 can be used as a new LUAD prognostic biomarker and can significantly extend the OS of LUAD patients. P2RY14 is crucial in preventing tumor cell immune escape from the LUAD microenvironment and may be connected to LUAD immune invasion.
Xu, Ting, et al. "P2RY14 downregulation in lung adenocarcinoma: a potential therapeutic target associated with immune infiltration." Journal of Thoracic Disease 14.2 (2022): 515.
Pubmed: 35280459 DOI: 10.21037/jtd-22-115